Blue Trust’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-690
Closed -$11.7K – 2541
2026
Q2
$11.7K Hold
690
– – ﹤0.01% 1821
2026
Q1
$10.2K Sell
690
-1,431
-67% -$20.9K ﹤0.01% 1837
2025
Q4
$33.8K Sell
2,121
-4,455
-68% -$63.2K ﹤0.01% 1491
2025
Q3
$72.7K Hold
6,576
– – ﹤0.01% 1221
2025
Q2
$55.7K Sell
6,576
-603
-8% -$4.83K ﹤0.01% 1412
2025
Q1
$57.7K Buy
7,179
+802
+13% +$6.5K ﹤0.01% 1266
2024
Q4
$57.3K Buy
6,377
+6,174
+3,041% +$50.4K ﹤0.01% 1230
2024
Q3
$1.16K Buy
+203
New +$1.26K ﹤0.01% 2681
2024
Q1
– Sell
-55
Closed – – 2193
2023
Q4
$0 Buy
+55
New +$453 ﹤0.01% 2480
2023
Q1
– Sell
-27
Closed – – 2297
2022
Q4
$0 Buy
+27
New +$157 ﹤0.01% 2224

Other funds holding AUPH

Blue Trust's AUPH Position: Q3 2026 in Review

Blue Trust sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2026, closing a stake of 690 shares — an estimated $11.7K sold.

Blue Trust first reported a position in AUPH in Q4 2022 and held it in 10 quarters. The position peaked at $72.7K in Q3 2025. 213 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Blue Trust reported no remaining Aurinia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Blue Trust sold 690 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $11.7K.
  • Blue Trust first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Blue Trust's Aurinia Pharmaceuticals position peaked at $72.7K in Q3 2025.
  • 213 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.